Biogen drops controversial Alzheimer's drug, focuses on other treatments
Biogen said it is discontinuing its controversial drug Aduhelm, so it can focus resources on other Alzheimer’s treatments that drive long-term growth. This includes shifting its priorities to its blockbuster drug Leqembi, which was developed with Japan's Eisai and approved in 2023. "As a pioneer…#biogen #aduhelm #leqembi #eisai #fda #irregularities #alzheimerassociation #newyorkcity #robertglatter #glatter (Source: Reuters: Health)
Source: Reuters: Health - February 2, 2024 Category: Consumer Health News Source Type: news

Alzheimer ’s Drug Aduhelm Went From Being Hailed A ‘Game Changer’ To A Dud
Biogen announced it will discontinue marketing the Alzheimer ’s drug Aduhelm. This ends the tortuous saga of a once-promising treatment for the memory-robbing disease. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 1, 2024 Category: Pharmaceuticals Authors: Joshua Cohen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation Editors' Pick editors-pick business pharma & standard Source Type: news

I was injected with growth hormones harvested from CORPSES as a child - now I'm at risk of Alzheimer's and another terrifying illness that can kill within a year
For the last 30 years, Dave Richardson has faced the terrifying prospect of being struck down with an incurable brain disease so deadly that it usually kills patients within a year. (Source: the Mail online | Health)
Source: the Mail online | Health - February 1, 2024 Category: Consumer Health News Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Investor Update - February 1, 2024 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
Group salesgrow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding COVID-19 products,Group sales increase by 8%Pharmaceuticals Divisionsalesincrease by 6% (excluding COVID-19 medicine Ronapreve: +9%) due to ongoing high demand for newer medicines, with eye medicine Vabysmo continuing to be the top growth driver, followed by Ocrevus (multiple sclerosis), Hemlibra (haemophilia A) and Polivy (blood cancer)Diagnostics Division salesare 13% lower due to high demand for COVID-19 tests in 2022; strong ...
Source: Roche Media News - February 1, 2024 Category: Pharmaceuticals Source Type: news

A fasting prime minister and a mind-reading billionaire: the week in science – podcast
Ian Sample and science correspondent Hannah Devlin discuss the big science stories of the week – from news that Elon Musk’s Neuralink has implanted its first chip into a human, to research suggesting Alzheimer’s can pass between humans in rare medical accidents, and the revelation that Rishi Sunak begins each week with a 36-hour fastClips: BBCContinue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - February 1, 2024 Category: Science Authors: Presented by Ian Sample with Hannah Devlin, produced by Eli Block, sound design by Tony Onuchukwu, the executive producer is Ellie Bury Tags: Science Medical research Neuroscience Elon Musk Alzheimer's Rishi Sunak Nutrition Technology Health Society Source Type: news

Ticker: Biogen to stop selling Alzheimer ’s drug; WynnBet, Betr look to exit Mass. mobile sports betting
Biogen will stop selling its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster that stumbled after its launch a few years ago. The Cambridge-based drugmaker also said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug…#biogen #cambridge #eisai #leqembi #fda #wynnbet #mass #massachusetts #betr #massgamingcommission (Source: Reuters: Health)
Source: Reuters: Health - January 31, 2024 Category: Consumer Health News Source Type: news

Controversial Alzheimer's Drug Abandoned
(MedPage Today) -- Biogen will discontinue its controversial Alzheimer's disease drug aducanumab (Aduhelm), the company announced Wednesday. The drugmaker will stop developing and selling aducanumab, an anti-amyloid monoclonal antibody that received... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 31, 2024 Category: Neurology Source Type: news

Biogen Is Dropping Controversial Alzheimer's Drug Aduhelm
WEDNESDAY, Jan. 31, 2024 -- Biogen, maker of the Alzheimer ' s medicine Aduhelm, announced Wednesday that it would " discontinue the development and commercialization " of the controversial drug.Biogen will return the rights to Aduhelm to Neurimmune,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 31, 2024 Category: General Medicine Source Type: news

Biogen will stop selling its controversial Alzheimer's drug Aduhelm
Biogen will stop selling its Alzheimer’s treatment Aduhelm (Source: ABC News: Health)
Source: ABC News: Health - January 31, 2024 Category: Consumer Health News Tags: Health Source Type: news

Biogen Plans to Shut Down Its Controversial Alzheimer ’ s Drug Aduhelm
Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago. The drugmaker said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug Administration, and it will stop sales of Aduhelm. [time-brightcove not-tgx=”true”] Patients taking doses of Aduhelm available through the commercial market can continue until November. A company representative said there are about 2,500 people worldwide taking Aduhelm. Biogen said it will turn its focus more to other tr...
Source: TIME: Health - January 31, 2024 Category: Consumer Health News Authors: Tom Murphy/AP Tags: Uncategorized healthscienceclimate wire Source Type: news

Biogen discontinues first Alzheimer's drug, goes all-in on Leqembi
Biogen is officially pivoting away from Aduhelm, the first Alzheimer's treatment the Cambridge drugmaker made. Biogen said over the past year it looked for potential partners or external financing for Aduhelm, but neither materialized. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 31, 2024 Category: Biotechnology Authors: Hannah Green Source Type: news

Neurimmune to regain global rights to brain amyloid depleter for the treatment of Alzheimer's disease
ZURICH, Switzerland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid. Aducanumab was granted FDA accelerated approval for the treatment of Alzheimer's disease. Neurimmune…#zurich #switzerland #neurimmune #fda #biogen #ip #gmp #christophhock #brain #fabianbuller (Source: Reuters: Health)
Source: Reuters: Health - January 31, 2024 Category: Consumer Health News Source Type: news

Biogen Drops Alzheimer's Drug Aduhelm, Ending a 17-year Chapter Biogen Drops Alzheimer's Drug Aduhelm, Ending a 17-year Chapter
Biogen will end a post-approval study of Alzheimer ' s treatment Aduhelm and return the licensing rights on the drug after failing to find a partner to mitigate costs of...Reuters Health Information (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - January 31, 2024 Category: Psychiatry Tags: Neurology & Neurosurgery Source Type: news

GLP-1 Drugs Tame Brain Inflammation; Novel Painkiller Succeeds; Headache as Metaphor
(MedPage Today) -- Glucagon-like peptide 1 (GLP-1) receptor agonists that reduce obesity also dial down brain inflammation, leading researchers to investigate how these agents might help treat Alzheimer's or Parkinson's disease. (Nature) IV ketamine... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - January 31, 2024 Category: Neurology Source Type: news